An indirect immunofluorescence technology platform for serological testing and antibody detection. The system is utilized for diagnosis of autoimmune and infectious diseases through fluorescence-based immunoassay methodology.
Manufactured by
Shenzhen, China
Founded in 2008, Shenzhen YHLO Biotech Co., Ltd. (YHLO) is a publicly listed company on the Science and Technology Innovation Board (stock code: 688575). Based in Shenzhen, YHLO excels in the research, development, production, sales, and service of in vitro diagnostic (IVD) products. Recognized as a national high-tech enterprise with extensive independent intellectual property rights, YHLO has earned numerous accolades, including being named a National Intellectual Property Demonstration Enterprise and one of Shenzhen's Top 70 Innovative Enterprises. YHLO utilizes six advanced IVD technology platforms, including chemiluminescence, biochemistry, indirect immunofluorescence, immunoblotting, fluorescent immunochromatography, and colloidal gold immunochromatography. With a portfolio of over 300 products addressing areas such as autoimmunity, reproductive health, infection, liver disease, and respiratory diseases, YHLO's products are widely implemented across hospitals, community clinics, and third-party testing centers, with a coverage rate exceeding 70% in China's top-tier hospitals. While firmly rooted in the domestic market, YHLO actively expands its international presence, with products exported to nearly 115 countries and regions, gaining recognition and trust from global customers. YHLO has made substantial investments in research and development, establishing research centers in Tokyo, Japan; Wuhan, China; and Changsha, China, as well as setting up a production base in Xiangtan, China. As of August 30, 2024, the company has filed for 681 patents, including 58 PCT patents, 367 invention patents, 167 utility model patents, and 22 design patents. YHLO prioritizes the integration of industry, academia, and research, establishing collaborative laboratories with prestigious institutions such as Peking University, the Institute of Biophysics of the Chinese Academy of Sciences, the Chinese University of Hong Kong (Shenzhen), the Southern University of Science and Technology, the Third People's Hospital of Shenzhen, Huazhong University of Science and Technology, and the National Innovation Center for High-Performance Medical Devices. YHLO adheres to the mission of Focus on healthcare, better life with technology, consistently striving for excellence and delivering outstanding products and services for human health, with the goal of being a leading enterprise in the life sciences and a global leader in in vitro diagnostics.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
ReLIA Bioengineering(Jiangsu), Inc
China · 1 relevant product
Beijing Zhongjian Antai Diagnostic Co., Ltd.
China · 1 relevant product
Xenta Biomedical Science Co.,Ltd
China · 3 relevant products
Vitrosens Biyoteknoloji Anonim Sirketi
Türkiye · 1 relevant product
S&T BioMed CO., LTD.
Taiwan · 1 relevant product
B&C Biological
China · 1 relevant product
Shenzhen Kingfocus Biomedical Engineering Co., Ltd.
China · 1 relevant product
ZIODIA Co., Ltd.
South Korea · 1 relevant product
Jiangsu Sunlant Bioengineering Co., Ltd.
China · 1 relevant product
23 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →1 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 38 closest product alternatives
Guangzhou Wondfo Biotech Co., Ltd. · China
Immunofluorescence-based diagnostic platform for detection and identification of specific antigens or antibodies in clinical samples. Provides fluorescence-based results for rapid point-of-care and laboratory testing.
ReLIA Bioengineering(Jiangsu), Inc · China
A diagnostic platform for point-of-care testing (POCT) that uses immunofluorescence technology for rapid and accurate detection. The platform features precise temperature control, multiple connectivity options, and automatic sample identification to enable quick diagnostic testing.
Beijing Zhongjian Antai Diagnostic Co., Ltd. · China
Fluorescence quantitative immunoassay platform for in vitro diagnostic testing of infectious diseases, respiratory pathogens, and gastrointestinal markers. The system enables quantitative analysis using fluorescence immunoassay technology with Class II medical device certification across multiple regulatory markets. Supports high-throughput diagnostic workflows in clinical laboratories and reference testing facilities.
Xenta Biomedical Science Co.,Ltd · China
An immunolayer chromatography technology platform utilizing fluorescence detection for rapid diagnostic testing. Provides high sensitivity across multiple analyte categories including thyroid markers.
Vitrosens Biyoteknoloji Anonim Sirketi · Türkiye
Immunofluorescence-based diagnostic platform for infectious disease detection providing accurate and fast results.
S&T BioMed CO., LTD. · Taiwan
Automated immunoassay system utilizing electrochemical detection methods for biomarker quantification. Suitable for high-throughput clinical laboratory applications.
B&C Biological · China
A fluorescence-based immunoassay platform from the POCT series designed for rapid diagnostic testing. The SF-100 platform enables high-sensitivity and high-precision immunofluorescence detection for various clinical analytes and sample types.
Shenzhen Kingfocus Biomedical Engineering Co., Ltd. · China
Quantum dot fluorescence-based platform for in vitro diagnostic applications. Supports development of various immunological assays with enhanced optical properties and batch consistency.
Xenta Biomedical Science Co.,Ltd · China
An easy-to-operate platform that supports whole blood direct testing with results available in as fast as 3 minutes. It offers high detection throughput of up to 450 tests per hour, includes a built-in thermal printer, and features dedicated tuberculosis detection functionality to provide efficient and reliable testing solutions for primary healthcare settings.
ZIODIA Co., Ltd. · South Korea
A platform for immune diagnosis devices based on Quantum Dot fluorescence measurement mode technology. It includes Quantum Dot labeled detection kits for enhanced sensitivity, precise analysis, and multiplex analysis capabilities. The platform offers both Gold Type and Quantum Dot Type kits with sensitivity down to ng/ml levels and 500-1,000 fold higher accuracy compared to gold standard detection methods.
Jiangsu Sunlant Bioengineering Co., Ltd. · China
A microarray-based chemiluminescence immunoassay platform using hard-substrate glass slides as carriers with covalently bound monoclonal antibodies. The platform features integrated positive and negative quality control points, multi-parameter detection with up to 56 array points, and a sandwich immunoassay methodology. It combines high-sensitivity chemiluminescence detection with high-throughput biochip technology using an integrated photoelectric sensor to read all signal points simultaneously.
Shenzhen Microprofit Biotech Co., Ltd · China
Point-of-care immunofluorescence test platform for rapid pathogen detection. Utilizes fluorescence technology for sensitive and specific clinical diagnostics.
26 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products